-  INCLUSION CRITERIA:

          -  Patients must have histologically confirmed gliosarcoma (primary or secondary) or
             primary central nervous system sarcoma confirmed by the Laboratory of Pathology, NCI.

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured bidimensionally by MRI (or CT scan if MRI is contraindicated).

          -  Patients must have failed standard therapy consisting of surgery, irradiation, and
             chemotherapy if indicated.

          -  Age greater than or equal to 18 years.

          -  Karnofsky greater than or equal to 60%.

          -  Patients must have normal organ and marrow function as defined below:

               -  leukocytes greater than or equal to 3,000/mcL

               -  absolute neutrophil count greater than or equal to 1,500/mcL

               -  platelets greater than or equal to 100,000/mcL

               -  total bilirubin within normal institutional limits

               -  AST(SGOT)/ALT(SGPT) less than or equal to 2.5 times institutional upper limit of
                  normal

               -  creatinine within normal institutional limits OR creatinine clearance greater
                  than or equal to 60 mL/min/1.73 m(2) for patients with

        creatinine levels above institutional normal.

          -  Patients must have the ability to understand and the willingness to sign a written
             informed consent document indicating that they are aware of the investigational nature
             of this study.

          -  The effects of sunitinib on the developing human fetus are unknown. For this reason
             and because anti-angiogenic agents are known to be teratogenic, women of child-bearing
             potential and men must agree to use adequate contraception (hormonal or barrier method
             of birth control; abstinence) prior to study entry and for the duration of study
             participation. Should a woman become pregnant or suspect she is pregnant while she or
             her partner is participating in this study, she should inform her treating physician
             immediately.

          -  Tumor tissue blocks or at least 10-15 unstained slides from the diagnosis should be
             available.

          -  At the time of registration, all subjects must be removed greater than or equal to 28
             days from any investigational agents.

        EXCLUSION CRITERIA:

          -  Patients who are receiving any other investigational agents.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Prior use of tyrosine kinase inhibitors or VEGF inhibition.

          -  Patients who are receiving strong CYP450 inducers or inhibitors are ineligible.

          -  Pregnant women are excluded from this study because sunitinib has potential for
             teratogenic or abortifacient effects. Because there is an unknown but potential risk
             for adverse events in nursing infants secondary to treatment of the mother with
             sunitinib, breastfeeding should be discontinued if the mother is treated with
             sunitinib.

          -  Patients with known HIV history on combination antiretroviral therapy are ineligible
             because of the potential for pharmacokinetic interactions with sunitinib. In addition,
             these patients are at increased risk of lethal infections when treated with
             marrow-suppressive therapy.

          -  Uncontrolled hypertension (> 150/100 mmHg) while on antihypertensive medications.

          -  New York Heart Association class II or greater congestive heart failure.

          -  Serious cardiac arrhythmia requiring medication.

          -  Baseline echocardiogram with ejection fraction < 50% or greater than or equal to 20%
             decrease from a prior study.

          -  QTc interval > 500 msec on baseline EKG

          -  Patients who require use of therapeutic doses of coumarin-derivative anticoagulants
             such as warfarin are excluded, although doses of up to 2 mg daily are permitted for
             prophylaxis of thrombosis. Note: Low molecular weight heparin is permitted provided
             the patient s INR is less than or equal to 1.5.

          -  Previous exposure to anthracyclines.